Lifco AB: Exercise of the over-allotment option in the listing of Lifco

Regulatory News:

Lifco AB: (STO:LIFCO)

SEB Corporate Finance ("SEB”) has today notified Lifco AB (publ) ("Lifco”) and Carl Bennet AB ("CBAB”) that the over-allotment option has been exercised in full in respect of 4,120,900 shares in Lifco.

In connection with the initial public offering of Lifco, CBAB granted SEB an over-allotment option of up to 4,120,900 series B shares to be used to cover so-called over-allotment of shares. SEB has exercised the over-allotment option in full. No stabilisation has been carried out since the listing, and due to Lifco’s share price development, SEB has decided to end the stabilisation period.

Following the exercise of the over-allotment option CBAB holds 45,513,260 shares in Lifco, corresponding to an ownership of approximately 50.1% of the shares and approximately 68.9% of the votes in Lifco.

About Lifco

Lifco acquires and develops market-leading niched operations with a potential to deliver sustainable profit growth. Lifco has three business areas: Dental, Demolition & Tools and Systems Solutions. Lifco’s management philosophy implies a long-term perspective on its holdings, focus on profitability and a highly decentralized organization. Lifco has about 100 subsidiaries in 30 countries. Lifco had a turnover of more than 6 billion SEK in 2013 and an EBITA-margin of 11.5 %. For more information, visit www.lifco.se.

Lifco announces this information in accordance with the Securities Market Act and/or the Act on Trading in Financial Instrument. The information was submitted for announcement at 6.00pm on 28 November 2014.

Important information

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Lifco AB (publ) ("Lifco” or the "Company") in any jurisdiction where such offer or sale would be unlawful. In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the "Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This document and the information contained herein are not for distribution or release, directly or indirectly, in or into the United States of America, Canada, Japan or Australia. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States, Canada, Japan or Australia or in any jurisdiction in which any offer or solicitation would be unlawful. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act”), and may not be offered or sold within the United States absent registration or pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons”). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

Any offering of securities will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the Company and its management, as well as financial statements. This document is an advertisement and not a prospectus for the purposes of the Prospectus Directive. Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the prospectus.

Matters discussed in this release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe," "expect," "anticipate," "intends," "estimate," "will," "may," "continue," "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond the Company’s control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements.

The information, opinions and forward-looking statements contained in this release speak only as at its date, and are subject to change without notice.

This information was brought to you by Cision http://news.cision.com